LOS ANGELES, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Kairos Pharma, Ltd., a clinical stage biopharmaceutical company developing cancer therapeutics designed to reverse cancer drug resistance and immune suppression, announces the dosing of its first two patients in its Phase 1 trial testing a combination therapy for its lead therapeutic candidate ENV105 in combination with osimertinib for the treatment of non-small cell lung cancer.
Kairos Pharma CEO John Yu stated, “The initiation of this trial speaks to the dedication of the Kairos team to execute on its goals to develop therapies for today’s unmet medical needs.”
The primary objective of this open-label trial is to evaluate the safety and tolerability of the combination therapy. The trial aims to enroll 60 patients who have developed clear resistance to osimertinib, as well as those who have shown partial sensitivity to the drug.
Lung cancer patients with epidermal growth factor receptor (EGFR) mutations typically receive EGFR-antagonists like osimertinib as a first line treatment. While effective initially, patients on osimertinib therapy eventually develop resistance. ENV105 is a first-in-class biologic developed to enhance the sensitivity of EGFR-driven lung cancer patients to EGFR-antagonists.
Dr. Neil Bhowmick, Chief Scientific Officer at Kairos Pharma, added, “It made sense to use ENV105 for such patients since blocking EGFR induced the target of ENV105, CD105, a known mediator of tumor progression.”
About Kairos Pharma
Based in Los Angeles, California, Kairos Pharma, Ltd. is a clinical-stage biopharmaceutical company focused on developing a diversified pipeline of cutting-edge oncology therapeutics that reverse the inhibitory effects of cancer on the immune system. The Company is advancing its portfolio of innovative drug candidates designed to reverse resistance and immune suppression from cancer.
CAUTIONARY STATEMENT CONCERNING FORWARD LOOKING STATEMENTS
This press release contains “forward-looking statements” as defined in the private Securities Litigation Reform Act of 1995 regarding clinical research surround ENV105. You can identify forward-looking statements as those that are not historical in nature, particularly those that use terminology such as “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential,” or “hopes” or the negative of these or similar terms. The reader is cautioned not to rely on these forward-looking statements. If underlying assumptions prove inaccurate, or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Kairos Pharma. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance. In evaluating these forward-looking statements, you should consider various factors, including: our success in completing newly initiated clinical trials, commence new trials, and obtain regulatory approval following the conclusion of such trials; challenges and uncertainties inherent in product research and development; and the uncertainty regarding future commercial success. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking statements discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties and assumptions about us. We are not obligated to publicly update or revise any forward-looking statement, and Kairos Pharma is not required to update any forward-looking statement as a result of new information or future events or developments.
Contact:
CORE IR
Louie Toma
ir@kairospharma.com
